AGAnne B. S. Giersch

Anne B. S. Giersch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anne B. S. Giersch has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinicopathologic evaluation of dedifferentiated liposarcoma lacking MDM2 amplification

    by Charlotte I Wang, Soma Jobbagy, Anne B Giersch, Jonathan B Greer, Kevin X Liu, Gregory M Cote, Yin P Hung, G Petur Nielsen, Ivan Chebib

    Introduction: Dedifferentiated liposarcoma (DDLPS) is a typically non‐lipogenic malignant neoplasm that arises from progression of an underlying atypical lipomatous tumour/well‐differentiated liposarcoma (ALT/WDLPS) and is classically defined by amplification of chromosome 12q15, including MDM2 and frequently cyclin‐dependent kinase 4 ( CDK4 ). Detection of MDM2 amplification by fluorescence in situ hybridization (FISH) and/or MDM2 protein expression immunohistochemistry (IHC) has, therefore, become central to the diagnosis of DDLPS, particularly in small biopsies from the retroperitoneum. Rare exceptions to this paradigm have been described, but the clinicopathologic and molecular spectrum of MDM2 non‐amplified DDLPS remains poorly characterized. We report a series of MDM2 non‐amplified DDLPS to better define their diagnostic features, genomic alterations and clinical behaviour. Methods: Pathology archives from 2010 to 2025 were queried for cases diagnosed as DDLPS. Inclusion criteria required a high‐grade sarcoma arising in a histologically confirmed ALT/WDLPS background, absence of MDM2 overexpression by IHC and lack of MDM2 amplification by FISH and/or single nucleotide polymorphism array. Clinicopathologic features, immunophenotype, treatment and outcomes were reviewed. Results: Among 253 cases of DDLPS identified during the study period, four (1.6%) fulfilled criteria for MDM2 ‐negative DDLPS. All tumours arose in the retroperitoneum or intra‐abdominal soft tissues and demonstrated high‐grade sarcoma morphology with an associated WDLPS component on resection. Despite the absence of MDM2 amplification, all cases showed strong CDK4 expression by IHC. Molecular analysis revealed recurrent alterations involving cell‐cycle regulation, including CDK4 copy number gain in all cases and loss of CDKN2A in three. Two cases harboured TP53 alterations. Clinically, outcomes were heterogeneous, ranging from aggressive disease with rapid recurrence and death within months to prolonged disease‐free survival exceeding 5 years. Conclusion: MDM2 non‐amplified DDLPS represents a rare subset of DDLPS that appear to be driven by alternative mechanisms of cell‐cycle dysregulation, most commonly involving CDK4 gain and CDKN2A loss, with occasional TP53 alterations. Awareness of this variant is critical to avoid misclassification as other high‐grade sarcomas, particularly on limited biopsies, and underscores the importance of integrating morphology, IHC and broad genomic profiling in diagnostically challenging retroperitoneal sarcomas.


  • Newborn Screening for Deafness/Hard of Hearing in the Genomic Era

    by Anne B S Giersch, Cynthia C Morton

    Background: Newborn hearing screening is a physiologic screen to identify infants who may be deaf or hard of hearing (DHH) and would benefit from early intervention. Typically, an infant who does not pass the newborn hearing screen is referred for clinical audiology testing, which may be followed by genetic testing to identify the etiology of an infant’s DHH. Content: The current newborn hearing screening paradigm can miss mild cases of DHH or later-onset DHH, leaving a child at risk for unrecognized DHH, which could impact long-term language, communication, and social development. Genomic technologies are improving the diagnosis of DHH in newborns who fail their newborn hearing screen, and a case is being made for genomic screening for DHH in all newborns. Summary: The genomic era brings a wealth of opportunities to screen newborns for genetic causes of hearing loss on a population wide basis, some of which are already being implemented in a clinical setting.


  • Open Access

    Commentary on Mosaic Copy Number Variation in a Patient with Cerebral and Pulmonary Arteriovenous Malformations and Recurrent Epistaxis

    by Anne B S Giersch

    Mosaic copy number variants (CNV) occur postfertilization and, depending on how early in embryonic/fetal development it occurs, the variant may be present in only a fraction of cells. Additionally, the variant may not be in all tissue types or in the same proportion of cells in different organs. These factors complicate the detection of mosaic CNVs, particularly if standard sequence analysis algorithms are used.

  • Open Access

    The Burden and Benefits of Knowledge: Ethical Considerations Surrounding Population-Based Newborn Genome Screening for Hearing

    by Calli O. Mitchell, Greysha Rivera-Cruz, Matthew Hoi Kin Chau, Zirui Dong, Kwong Wai Choy, Jun Shen, Sami Amr, Anne B. S. Giersch, Cynthia C. Morton

    Recent advances in genomic sequencing technologies have expanded practitioners’ utilization of genetic information in a timely and efficient manner for an accurate diagnosis. With an ever-increasing resource of genomic data from progress in the interpretation of genome sequences, clinicians face decisions about how and when genomic information should be presented to families, and at what potential expense. Presently, there is limited knowledge or experience in establishing the value of implementing genome sequencing into newborn screening. Herein we provide insight into the complexities and the burden and benefits of knowledge resulting from genome sequencing of newborns.


  • SEQuencing a baby for an optimal outcome: a genomic future for newborn screening

    by Anne Giersch, Jun Shen, Kevin Booth, Yvonne Chekaluk, Michael Cohen, Katherine Gregory, Jennifer Hochschild, Linda Johnson, Margaret Kenna, Joel Krier, et al.